Article

<i>TP53</i> abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

2020-02-28

Abstract excerpt

<h4>Purpose</h4> Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37-46% of acute myeloid leukemia (AML) cases with adverse risk cytogenetics and are associated with primary induction failure (PIF), high risk of relapse and dismal prognosis. Herein, we aimed to characterize the immune landscape of TP53 mutated AML and to determine whether TP53 abnormalities identify a patient subgro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 87c7b9cf-addf-52bd-aeb0-b487b1fc7c52
DOI: 10.1101/2020.02.28.961391

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>TP53</i> abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemiaDOI 10.1101/2020.02.28.961391Read

Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.Semantic proximity Read

Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemiaSemantic proximity Read

Elucidating the immune landscape and potential prognostic model in acute myeloid leukemia with TP53 mutation.Semantic proximity Read

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia.Semantic proximity Read

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.Semantic proximity Read

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemiaSemantic proximity Read

Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53Semantic proximity Read

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read

Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidineSemantic proximity Read

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.Semantic proximity Read

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read

Immune-based subgroups uncover diverse tumor immunogenicity and implications for prognosis and precision therapy in acute myeloid leukemia.Semantic proximity Read